Nontyphoidal salmonellae, particularly Salmonella enterica serovar Typhimurium, are a major cause of invasive disease in Africa, affecting mainly young children and HIV-infected individuals. Glycoconjugate vaccines provide a safe and reliable strategy against invasive polysaccharide-encapsulated pathogens, and lipopolysaccharide (LPS) is a target of protective immune responses. With the aim of designing an effective vaccine against S. Typhimurium, we have synthesized different glycoconjugates, by linking O-antigen and core sugars (OAg) of LPS to the nontoxic mutant of diphtheria toxin (CRM 197 ). The OAg-CRM 197 conjugates varied in (i) OAg source, with three S. Typhimurium strains used for OAg extraction, producing OAg with differences in structural specificities, (ii) OAg chain length, and (iii) OAg/CRM 197 ratio. All glycoconjugates were compared for immunogenicity and ability to induce serum bactericidal activity in mice. In vivo enhancement of bacterial clearance was assessed for a selected S. Typhimurium glycoconjugate by challenge with live Salmonella. We found that the largest anti-OAg antibody responses were elicited by (i) vaccines synthesized from OAg with the highest glucosylation levels, (ii) OAg composed of mixed-or medium-molecular-weight populations, and (iii) a lower OAg/CRM 197 ratio. In addition, we found that bactericidal activity can be influenced by S. Typhimurium OAg strain, most likely as a result of differences in OAg O-acetylation and glucosylation. Finally, we confirmed that mice immunized with the selected OAg-conjugate were protected against S. Typhimurium colonization of the spleen and liver. In conclusion, our findings indicate that differences in the design of OAg-based glycoconjugate vaccines against invasive African S. Typhimurium can have profound effects on immunogenicity and therefore optimal vaccine design requires careful consideration.
S
almonella enterica serovars Typhimurium and Enteritidis generally cause mild gastroenteritis in developed countries but are a predominant cause of invasive bloodstream infection in sub-Saharan Africa, especially among young children and HIV-infected individuals (1, 2) . The case-fatality rate of invasive nontyphoidal Salmonella (iNTS) disease, mainly caused by serovars Typhimurium and Enteritidis, is ca. 20%, and the effectiveness of antibiotic treatment is impaired by a growing frequency of multidrug resistance. Currently, there are no licensed vaccines against iNTS disease, and efforts are ongoing to identify protective antigens and best strategies for vaccine development.
Although salmonellae are facultative intracellular bacteria, they are vulnerable to serum immunoglobulins which can mediate bacteriolysis and osponophagocytosis (3, 4) . Previous work from Malawi has shown that antibodies against S. Typhimurium and S. Enteritidis develop with age in African children, the timing corresponding with a decline in iNTS cases (3) .
Approaches to develop an effective vaccine able to elicit a protective immune response include live oral vaccines, which are logistically easy to administer but have potential problems regarding efficient colonization and reactogenicity (5, 6) , or subunit vaccines, which could be protein (7, 8) or polysaccharide based, including glycoconjugate vaccines (9) (10) (11) (12) (13) . Conjugate vaccines have provided a safe and reliable strategy against invasive polysaccharide-encapsulated pathogens such as Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis (14) (15) (16) . For NTS, lipopolysaccharide (LPS) has been implicated as a target of the protective immune response (17, 18) . LPS is composed of lipid A (endotoxin), attached to the 3-deoxy-D-manno-octulosonic acid (KDO) terminus of a highly conserved core region, which is linked to a variable O-antigen chain containing serovarspecific repeating units (19) . The O-antigen chain of Salmonella contains a trisaccharide backbone of ¡2)-D-mannose-(1¡4)-Lrhamnose-(1¡3)-D-galactose-(1¡, which is common for Salmonella groups A, B, and D, with a serovar-specific dideoxyhexose side chain attached to the mannose residue, such as abequose for S. Typhimurium and tyvelose for S. Enteritidis (providing O:4 and O:9 specificities, respectively), and glucose branches. Group B salmonellae, such as S. Typhimurium, can also express the O:5 epitope, resulting from the O-acetylation of the 2-hydroxyl group of the abequose residue (O:4,5) (20) . LPS protects bacteria from the environment and from complement (3, 21) , which can lead to bacterial killing by membrane attack complex formation. However, the ability of LPS to resist complement deposition can be overcome by the production of specific antibodies against O-antigen (22, 23) . The O-antigen chain and core sugar alone (here referred to as OAg) constitute a poor immunogen. In contrast, OAg conjugated to a carrier protein can result in protective immunity against lethal challenge, and anti-OAg antibodies are protective in adoptive transfer experiments (9, 12, 13, 24, 25) .
In the present study, we synthesized glycoconjugate vaccines against S. Typhimurium, with OAg linked to the nontoxic mutant of diphtheria toxin, CRM 197 (26) . OAg was extracted by acetic acid hydrolysis directly from the bacterial pellet, a process that removes the toxic lipid A by cleaving the labile bond between lipid A and the KDO sugar at the end of the core region (27) . The KDO was used for covalent linkage of OAg to CRM 197 through a conjugation chemistry that does not modify the structure of the polysaccharide chain (28) . conjugates varied with regard to (i) OAg source, with use of three Typhimurium strains (D23580, NVGH1792, and LT2) producing OAg with specific structural differences, (ii) OAg molecular weight (MW) distribution, with conjugates containing OAg populations of different chain length, and (iii) OAg/CRM 197 ratio. Our objective was to gain insights into optimized NTS vaccine design by comparing the immunogenicity and induced serum bactericidal activity of the different OAg-CRM 197 conjugate vaccines.
MATERIALS AND METHODS
Origin and growth of bacterial strains. The clinical isolate S. Typhimurium D23580 was obtained from the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. D23580 is a representative Malawian isolate belonging to the ST313 sequence type isolated from a case of iNTS disease (29, 30) . S. Typhimurium NVGH1792 was obtained from the University of Birmingham (27) . S. Typhimurium LT2 and S. Enteritidis CMCC4314 (corresponding to ATCC 4931; this strain was used in control experiments) were obtained from the Novartis Master Culture Collection (NMCC). All Salmonella strains were grown in chemically defined medium, using glycerol as the carbon source. D23580, NVGH1792, and LT2 were fermented in a 7-liter bioreactor (EZ-Control; Applikon) to an optical density (OD) of 35, as previously described (27, 31) .
OAg extraction and purification. OAg was directly extracted from the fermentation broth and purified as previously described (27) . Briefly, the growth culture was subjected to 2% acetic acid hydrolysis (3 h at 100°C), and the cell supernatant, containing free OAg, was collected after centrifugation. Lower-molecular-weight impurities were removed and the cell supernatant was concentrated by tangential flow filtration (TFF), using a Hydrosart 30-kDa membrane. Protein and nucleic acid impurities were coprecipitated in 20 mM citrate buffer at pH 3. Proteins were further removed by ion-exchange chromatography, and nucleic acids by precipitation in 18 mM Na 2 HPO 4 , 24% ethanol, and 200 mM CaCl 2 . OAg was recovered in water by a second TFF 30-kDa step. Purified OAg from the three S. Typhimurium strains were run on a HiPrep Sephacryl S100 HR16/60 column in 50 mM NaH 2 PO 4 -150 mM NaCl (pH 7.2) at a 0.5-ml/min flow rate to separate OAg populations of different MWs. Corresponding fractions were pooled and desalted on a HiPrep 26/10 desalting column (53 ml) prepacked with Sephadex G-25 Superfine (GE Healthcare) prior to conjugation.
OAg characterization. All OAg preparations were characterized using a range of analytical methods (27, 28) : (i) phenol sulfuric acid assay for total sugar quantification (32); (ii) micro-BCA for protein quantification (using bovine serum albumin as a reference according to the manufacturer's instructions [Thermo Scientific]); (iii) UV spectroscopy for nucleic acid content (assuming that a nucleic acid concentration of 50 g/ml gives an OD 260 of 1); (iv) chromogenic kinetic LAL (Limulus amebocyte lysate) for endotoxin level (Charles River Endosafe-PTS instrument); (v) sizeexclusion high-pressure liquid chromatography (HPLC-SEC; differential refractive index [dRI] detection) to estimate molecular size distribution of OAg populations; (vi) high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) for sugar composition analysis; (vii) semicarbazide/HPLC-SEC method for KDO sugar quantification; and (viii) proton nuclear magnetic resonance ( 1 H NMR) analysis to identify OAg samples and quantify O-acetylation level.
OAg conjugation to CRM 197 . S. Typhimurium OAg-CRM 197 conjugates were synthesized by adapting the method previously reported for S. Paratyphi OAg (28) . Briefly, OAg was derivatized with adipic acid dihydrazide (ADH) by reductive amination of the KDO sugar and linked to the amino groups on the protein after attachment of a second linker, adipic acid bis(N-hydroxysuccinimide) (SIDEA), to ADH. CRM 197 was obtained from Novartis Vaccines and Diagnostics.
Purification and characterization of OAg-CRM 197 conjugates. Conjugates were purified either by size exclusion chromatography on a 1.6-by-90-cm S-300 HR column eluted at 0.5 ml/min in 50 mM NaH 2 PO 4 -150 mM NaCl (pH 7.2) or by using a Phenyl-HP column, loading 500 g of protein for ml of resin in 50 mM NaH 2 PO 4 -3 M NaCl (pH 7.2). The purified conjugate was eluted in water, and the fractions collected were dialyzed against 10 mM NaH 2 PO 4 (pH 7.2).
Purified conjugates were characterized by phenol sulfuric acid assay (32) for determining the total sugar content, micro-BCA for determining the total protein content, and HPLC-SEC for verifying conjugate formation in comparison to free protein and free OAg and to estimate the conjugate MW distribution (28) .
Immunogenicity and challenge studies. Two immunogenicity studies were conducted (i) to compare the immunogenicities of glycoconjugates made with D23580 OAg populations of different MWs and (ii) to compare the immunogenicities of glycoconjugates made with OAg derived from D23580, NVGH1792, and LT2 S. Typhimurium strains. Whole, unconjugated S. Typhimurium LPS used in the first study was obtained from a commercial source (Enzo Life Sciences, catalog no. ALX-581-011-L002). The glycoconjugate dose was quantified in terms of the OAg amount.
In both studies, 5-week-old female C57BL/6 mice were purchased from Charles River Laboratories. Mice were injected subcutaneously three times, at 2-week intervals, with immunogen (200 l/dose). Mice were bled, and sera were collected before the first immunization (day 0), on immunization days 14 and 28, and again 2 weeks after the third immunization on day 42. All animal protocols were approved by the local animal ethical committee (approval N. AEC201018) and by the Italian Minister of Health in accordance with Italian law.
A third mouse experiment was performed to evaluate the in vivo efficacy of the selected D23580 conjugate (OAg containing mixed-MW populations). This experiment was performed in observance of licensed procedures under United Kingdom Animals (Scientific Procedures) Act 1986. Two groups of six 8-to 10-week-old female C57BL/6N mice, bred in-house at the Wellcome Trust Sanger Institute (33) , were vaccinated subcutaneously with either 1 g of conjugate or saline/dose, as described above. At day 45, mice were challenged intraperitoneally with 10 4 CFU of D23580 and sacrificed at 24 h postchallenge. The spleens and livers were homogenized in water, and viable bacterial counts were determined by plating on Luria-Bertani (LB) agar.
Serum antibody analysis by ELISA. Serum IgG levels against both OAg and CRM 197 were measured by enzyme-linked immunosorbent assay (ELISA) (28, 31, 34) . Purified OAg from D23580, NVGH1792, or LT2 (5 g/ml) and CRM 197 (2 g/ml) were used for ELISA plate coating. Mouse sera were diluted 1:200 in phosphate-buffered saline (PBS) containing 0.05% Tween 20 and 0.1% bovine serum albumin (BSA). ELISA units were expressed relative to mouse anti-OAg (generated by immunizing mice with heat-killed D23580 [34] ) or anti-CRM 197 IgG standard serum curves, with the best four-parameter fit determined by a modified Hill plot. One ELISA unit was defined as the reciprocal of the standard serum dilution that gives an absorbance value equal to 1 in the assay. Each mouse serum was tested in triplicate. The data are presented as scatter plots of individual mouse ELISA units, with the geometric mean of each group. The data from the second immunization study are presented as reverse cumulative distribution (RCD) plots, with antibody levels on the horizontal axis (logarithmic scale), and the percentages of mice with an antibody concentration equal to or greater than the level indicated on the vertical axis (range, 0 to 100%) (35) .
SBA. Equal volumes of day 42 mouse serum belonging to the same immunization group were pooled for serum bactericidal assay (SBA) experiments. Sera from mice immunized with NVGH1792 conjugate were also tested individually.
S. Typhimurium was grown in LB medium to log phase (OD ϭ 0.2), diluted 1:30,000 in SBA buffer (50 mM phosphate, 0.041% MgCl 2 ·6H 2 O, 33 mg/ml CaCl 2 , 0.5% BSA) to approximately 3 ϫ 10 3 CFU/ml, and distributed into sterile polystyrene U-bottom 96-well microtiter plates (12.5 l/well). To each well (final volume of 50 l [ϳ620 CFU/ml]), serum samples serially diluted 3-fold (starting from a 1:20 or a 1:100 dilution) were added. Sera were heated at 56°C for 30 min to inactivate endogenous complement. Active baby rabbit complement (BRC; PelFreez lot 0405/lot 12521) used at 50% of the final volume was added to each well. The BRC source, lot, and percentage used in the SBA reaction mixture were previously selected for lowest toxicity against S. Typhimurium. To evaluate possible nonspecific inhibitory effects of BRC or mouse serum, bacteria were also incubated with either the same tested sera plus heat-inactivated BRC (HI-BRC), sera alone (no BRC), or SBA buffer and active BRC. Each sample and control was tested in triplicate. A 7-l reaction mixture from each well was spotted onto LB agar plates at time zero (T0) to assess the initial CFU and at 1.5 h (T90) after incubation at 37°C. LB agar plates were incubated overnight at 37°C, and the resulting CFU were counted the following day. The bactericidal activity was determined as the percent CFU counted in each pooled serum dilution with active or inactive BRC compared to the CFU of the same serum dilutions with no BRC. SBA graphs show the percent bacterial growth as a function of antiOAg ELISA units detected in each tested serum pool.
Flow cytometry for anti-Salmonella IgG antibodies. Bacteria were grown overnight in LB medium, diluted to an OD of 0.17, and incubated in 1:200-diluted (PBS, 1% BSA) serum samples (3 ϫ 10 6 CFU in 50 l) for 1 h in ice. After a washing step with PBS, the bacteria were incubated with secondary anti-mouse Alexa Fluor 647-labeled antibody (Molecular Probes; 1:400 in PBS-1% BSA) for 1 h in ice. After further washing, the bacteria were resuspended in 4% formaldehyde (130 l) and then read using a FACSCanto (BD Biosciences) flow cytometer (10,000 events recorded). We used, as negative controls, bacteria incubated with secondary antibody only. Values were obtained by dividing the geometric mean of fluorescent signals of positive bacteria compared to the negative controls.
Statistical analysis. Statistical analysis of ELISA results was conducted on day 42 samples (with mice receiving 8 g/dose for the first study and 0.125 g/dose for the second study). Groups were compared using Kruskal-Wallis one-way analysis of variance. Post hoc analysis was performed using the Student-Newman-Keuls test for both anti-OAg and anti-CRM 197 antibody units (using ␣ ϭ 0.05). The dose-response relationship in the first study was evaluated by Spearman rank correlation. Statistical evaluation of SBA growth inhibition of different serum/antibody preparations was performed using a Student t test at each serum dilution.
RESULTS
OAg purification and characterization. S. Typhimurium strains grew well under the fermentation conditions used (doubling times: 1.2 h, D23580; 1.4 h, NVGH1792; and 1.6 h, LT2), reaching high cell densities (see Fig. S1 in the supplemental material).
Purification yields were 250 to 400 mg of OAg per liter of fermentation broth according to strain of origin. All purified OAg were found to have protein and nucleic acid contents of Ͻ1% (wt/wt) with respect to OAg and endotoxin levels of Ͻ0.1 EU/g of sugar, indicating the complete removal of lipid A (27) .
OAg from the three different strains were similar in terms of MW distribution (27) . Analysis by HPLC-SEC (dRI) revealed, for all of them, the presence of two main populations with different average molecular masses (indicated in kDa, which is the distribution coefficient in size-exclusion chromatography, indicating the OAg molecular mass, measured as 0.58 and 0.68 on TSK gel 6000-5000 PW columns, 0.5 ml/min, 100 mM NaH 2 PO 4 100 mM NaCl, 5% CH 3 CN [pH 7.2]). Sugar composition analysis by HPAEC-PAD and 1 H NMR (Table 1) revealed mannose (Man), rhamnose (Rha), and galactose (Gal) in a molar ratio of 1:1:1, as expected, and an abequose (Abe)/Rha molar ratio close to 1 for all of the strains. The glucose (Glc)/Rha molar ratio was similar for LT2 (0.11) and NVGH1792 (0.08) but was much higher for D23580 OAg (0.39).
The O-acetyl content (expressed as the percent molar ratio of O-acetyl groups to Rha) was also different according to the OAg source: 142% for D23580, 149% for NVGH1792, and 65% for LT2 OAg. For D23580 and NVGH1792, percentages higher than 100 indicate the presence of O-acetyl groups in more than one position per OAg repeating unit (Table 1) . Analyses by 1 H NMR (Fig.  1) indicated the presence of O-acetyl groups on C-2 of Abe for OAg from each strain and the additional presence of O-acetyl groups on Rha for D23580 and NVGH1792 OAg (36, 37) .
For each strain, the two populations at different MWs were separated by size exclusion chromatography and fully characterized (Table 1 ). Higher-MW (HMW) and lower-molecular-weight (indicated here as the medium-molecular-weight [MMW]) populations were identical in terms of O-acetylation level and sugar composition, differing only in their MWs. The average number of repeating units was calculated based on the molar ratio of Rha (present in each repeating unit) to N-acetylglucosamine (GlcNAc; present as a unique sugar in the core region). For all OAg, the ratio of KDO to GlcNAc was close to 1, confirming the presence of one KDO unit per OAg chain. 
Synthesis and characterization of OAg-CRM 197 conjugates.
Acid hydrolysis cleaves the labile linkage between the lipid A and the KDO sugar at the proximal end of the core region, releasing OAg. This sugar has been used to introduce ADH and then SIDEA linkers and to bind OAg to the carrier protein, CRM 197 , without modifying the OAg sugar chain (28) .
Conjugates were prepared using OAg purified from the three different strains, without separating the two populations of different MWs (OAg mix ). For D23580 OAg, conjugates were also prepared with the isolated populations of different MWs to investigate the influence of OAg chain length on the immunogenicity of the corresponding conjugate vaccines. All conjugation mixtures were free from residual free CRM 197 , as shown by SDS-PAGE and HPLC-SEC. The purification of the D23580 MMW OAg conjugate from free polysaccharide was performed by size-exclusion chromatography. For conjugates with mixed HMW and MMW OAg populations, the conjugate overlapped the population of free HMW OAg on the Sephacryl S300 column, so purification of such conjugates was performed by hydrophobic interaction through a Phenyl-HP column, loading the conjugation mixture in 3 M NaCl. Free OAg did not bind to the resin and was removed in the flowthrough. The purified conjugate was eluted in water. Conditions used were optimal for the recovery of the LT2 OAg conjugates (79% conjugate recovery in terms of protein) but not for D23580 and NVGH1792 conjugates (50% conjugate recovery), possibly because of the higher O-acetylation levels of D23580 and NVGH1792 OAg. When purifying D23580 OAg HMW -CRM 197 , the average size of the conjugate lost in the flowthrough was bigger than in the eluate. The flowthrough population was further purified from free OAg by size-exclusion chromatography and was characterized by a higher OAg/CRM 197 ratio than the conjugate retained on the phenyl column (9.2 and 3.1, respectively).
The main characteristics of the conjugates are listed in Table 2 . K d values for all of the conjugates were lower than unconjugated CRM 197 (0.72) and both unconjugated HMW (0.58) and MMW (0.68) OAg, indicating that all conjugates are of higher molecular weight compared to their unconjugated component parts.
Immunogenicity studies. In the first study (Table 3) , eight C57BL/6 mice per group were immunized subcutaneously three times at 2-week intervals with two glycoconjugates containing OAg extracted from D23580 at doses ranging from 0.125 to 8 g: OAg mix -CRM 197 , synthesized using a mix of both OAg populations, and OAg MMW -CRM 197 , produced after selecting the MMW OAg population. Additional groups contained mice immunized with unconjugated OAg, a physical mixture of OAg and CRM 197 , commercial S. Typhimurium LPS, and saline only.
As shown in Fig. 2a , both OAg-CRM 197 conjugate formulations generated an antibody dose response (P Ͻ 0.001) and were immunogenic at the lowest dose tested (0.125 g) with significantly higher levels of anti-OAg IgG compared to unconjugated OAg and the OAg and CRM 197 physical mixture. No significant difference in anti-OAg titers was found between the two conjugate groups. Unconjugated OAg alone or mixed with CRM 197 did not elicit a detectable antibody response (Ͻ10 anti-OAg ELISA units) to OAg (Fig. 2a) . Also, for anti-CRM 197 antibodies, no significant difference was found between the two conjugate groups, and for both groups a dose-response relationship was detected (P Ͻ 0.001). As expected, the OAg and CRM 197 mixture generated anti-CRM 197 antibodies (Fig. 2b) .
In the second study (Table 3) , 20 mice per group were immunized with glycoconjugates derived from D23580-, NVGH1792-, and LT2-OAg, using a mixture of both OAg size populations for each conjugation, without further purification. The D23580 MMW and D23580 mix conjugates from the first study were included as 197 wt/wt ratios of 3.1 and 9.2, respectively. Unconjugated NVGH1792 OAg was used as a further control. In the present study, the lower suboptimal immunization dose of 0.125 g was deliberately chosen based on the findings of the first study in order to increase discrimination between responses to the different conjugates. This dose was not selected with the aim of inducing optimal antibody responses, and so there was marked variability in antibody responses within each group and the presence of many nonresponder mice. For this reason, data are also represented as RCD plots (Fig. 3b and c) , which allow comparisons of the full distribution of antibody data and display outliers without distortions (35) . As shown in Fig. 3a (Fig. 3c) , the highest anti-OAg IgG antibody titers were obtained with D23580 OAg mix -CRM 197 conjugate (P Ͻ 0.001). The more rectangular curve obtained with this conjugate indicated that a high proportion of mice had antibody levels near the high end of the included range. In contrast, for both NVGH1792 and LT2 OAg mix -CRM 197 conjugates, the majority of mice had IgG antibody levels below the MLD (7 ELISA units for this assay), with 12/20 mice of the NVGH1792 group and 8/20 mice of the LT2 group being nonresponders (only 1/20 for D23580). The difference in the responses of the NVGH1792 and LT2 groups was not statistically significant. The D23580 OAg mix -CRM 197 conjugate was significantly more immunogenic than the NVGH1792 and LT2 conjugates (P Ͻ 0.001), regardless of whether ELISA plates were coated with OAg from D23580 or NVGH1792 (Fig. 3d) . When LT2 OAg was used as plate-coating agent, very low ELISA signals were obtained with all immunization groups, with 3/20 mice above the MLD per group at most (no significant differences [data not shown]).
SBA. To evaluate the functional activity of elicited antibodies, sera from immunized mice were tested using an SBA. Both D23580 conjugates tested in the first study induced antibodies with high SBA activity ( Fig. 4a and b No growth inhibition was found with sera from unconjugated OAg (Fig. 4a) or from OAg mixed with CRM 197 and LPS groups (data not shown), which were both similar to the negative control (OAg MMW -CRM 197 with heat-inactivated BRC). Antibodies induced by D23580 OAg mix conjugate were bactericidal against both NVGH1792 and LT2 strains, with comparable levels of growth inhibition, as seen with D23580 (Fig. 4c) . As expected, SBA was OAg serovar specific, with no growth inhibition occurring when sera were tested against S. Enteritidis (O:9 antigen, CMCC4314 strain, Fig. 4c) .
SBA activity was also tested for the conjugates of the second study, generated using different strain-specific OAg (and for D23580, using OAg at different MWs) (Fig. 5a) . Sera from mice immunized with the LT2 OAg mix conjugate showed the lowest SBA activity compared to sera from NVGH1792 and D23580 OAg mix -CRM 197 immunizations against D23580 (significant differences between LT2 and NVGH1792/D23580 OAg mix -CRM 197 at dilutions of 1:540 to 1:4,860 and 1:540 to 1:1,620 [P Յ 0.03 and P Յ 0.02]). However, when SBA activities were normalized per ELISA unit of anti-S. Typhimurium OAg IgG, the bactericidal activity induced by the LT2 conjugate overlapped that of D23580 OAg-CRM 197 (Fig. 5b) , while the NVGH1792 conjugate yielded significantly more growth inhibition per ELISA unit (P Ͻ 0.01 in an ELISA unit interval of 0.01 to 0.3). We further investigated the relationship between anti-OAg antibody amounts and SBA activity by testing sera from individual mice from the NVGH1792 conjugate group for ability to kill D23580 (see Fig. S2 in the supplemental material). All mouse sera (except for one mouse) produced strong growth inhibition with Ͼ1 ELISA units. However, the anti-OAg IgG ELISA units for 50% killing of D23580 ranged between 0.003 and 0.3 ELISA units, corresponding to serum dilutions 1:20 to 1:30,000, suggesting that antibody quality, as well as quantity, determines bactericidal potential of individual sera.
When comparing responses to D23580 conjugates of different MWs, sera from mice immunized with D23580 OAg HMW conjugates produced less SBA activity than sera from mice immunized with conjugates containing D23580 OAg MMW and OAg mix (Fig.  5a) , a finding consistent with the ELISA results (Fig. 3a) . However, after normalization per ELISA units, overlapping SBA curves were found for all conjugate sera, indicating that antibodies induced by conjugates with different lengths of D23580 OAg had similar bactericidal activities (Fig. 5c) .
Flow cytometry.
To evaluate possible differences in cell surface binding, sera from mice immunized with D23580, NVGH1792, or LT2 conjugates were tested by fluorescence-activated cell sorting (FACS) against both homologous and heterologous strains of S. Typhimurium (Fig. 6 ). Both D23580 and NVGH1792 conjugates elicited anti-OAg IgG with good binding capacity against D23580 and NVGH1792 but poor recognition of LT2. In contrast, LT2 OAg-conjugate elicited antibodies that could bind all three strains similarly.
Mouse challenge experiment. In order to confirm the potential in vivo efficacy of an S. Typhimurium O-antigen-CRM 197 conjugate vaccine, we performed a Salmonella challenge study. Based on the immunogenicity results obtained with the different conjugates, D23580 OAg mix -CRM 197 was selected for this study. Mice were immunized on days 0, 14, and 28 and challenged with D23580 on day 45. Spleens and livers were examined for bacterial burden 24 h later. Immunized mice showed a 2-log reduction compared to unimmunized control mice in the bacterial colonization of spleens and livers after challenge (Fig. 7) .
DISCUSSION
Salmonella Typhimurium is among the most important causes of bacterial bloodstream infections in Africa. The huge burden of iNTS disease-estimated at ϳ1 million clinical cases per yearcoupled with high mortality (around 200,000 deaths/year), multidrug resistance, and difficulty in diagnosis (1) makes this disease a high priority for vaccine development.
Conjugation of a polysaccharide antigen to a carrier protein constitutes a strategy of proven effectiveness to enhance the immunogenicity of polysaccharide alone by inducing T-helper cell- mediated antibody responses (38, 39) . To design glycoconjugates with the potential of being effective vaccines, several biochemical factors need to be evaluated that can affect the immunogenicity and tolerability of the final product. Among the most important parameters are the carrier protein (9, 40, 41) and the conjugation chemistry chosen (9, 12, 42) , but additional factors, including the molecular weight (MW) of the polysaccharide (43) (44) (45) , saccharide modifications (such as O-acetylation and glucosylation) (12, 43) , and the sugar/carrier ratio (25, 44, 46) , need to be explored (47) .
With the aim of designing effective glycoconjugate vaccines against iNTS disease, we generated a range of conjugates, by extracting OAg from three different S. Typhimurium strains (Table  1) and coupling them to CRM 197 (Table 2) , a carrier widely used in licensed vaccines for routine infant immunization (26) . Since S. Typhimurium OAg size and structure impact the immune response (25, 48, 49) , we investigated both aspects by producing strain-specific conjugates, with OAg populations differing only for the average MW and OAg/CRM 197 ratio (D23580 OAg vaccines) and strain-variant conjugates, with OAg differing for both O-acetylation (position and amounts of O-acetyl groups) and glucosylation levels.
In all strains tested, we observed a bimodal distribution of OAg size, as previously described (49, 50) , with two main populations of OAg: one at a higher MW (OAg HMW ) and one at a medium MW (OAg MMW ), representing averages of 70 to 95 OAg repeating units and 25 to 35 OAg repeating units, respectively. OAg with even lower MWs were also detected but not purified, as previous work has shown a lack of immunogenicity for such preparations, when mainly constituted by core sugars (25, 43) . Considering that OAg length can be regulated by the wzz genes, which are influenced by growth conditions (51, 52) , all strains were grown in the same medium.
When the immunogenicities of D23580 conjugates prepared with OAg from different MW populations were compared, there was no difference for OAg MMW and OAg mix conjugates (Fig. 2a  and 4a) . A possible explanation for this could be that in OAg mix conjugates, the OAg MMW population outcompetes the OAg HMW fraction during conjugation, resulting in OAg mix conjugates that would predominantly contain OAg MMW . Conjugates made with the OAg HMW population were considerably less immunogenic than those made using OAg MMW or OAg mix . In particular, the OAg HMW(9.2) conjugate, at the low dose used, could not elicit any anti-OAg antibody response detectable by our ELISA (Fig. 4a) With the aim of evaluating the specific bactericidal potential of anti-OAg IgG elicited by each D23580 conjugate, irrespective of amount of serum antibodies (Fig. 5a) , SBA activity was normalized for anti-OAg IgG ELISA units (Fig. 5c) . A similar bactericidal activity was found for all D23580 conjugates, indicating that the intrinsic antibody bactericidal properties were similar for all conjugates synthesized using different OAg sizes from the same strain.
To evaluate whether fine differences in OAg structure may influence immunogenicity, OAg mix from three different strains were conjugated to CRM 197 and tested in mice. These OAg were similar in terms of MW distribution but differed in glucosylation levels (41% for D23580 OAg compared to 8 and 11% for LT2 and NVGH1792 OAg, respectively) and O-acetylation levels and positions (D23580 and NVGH1792 OAg have twice the O-acetylation levels of LT2, with more than one O-acetyl group present per OAg repeating unit) ( Table 1 , Fig. 1 ) (37) . Such modifications of OAg fine specificities can be caused by bacteriophages (36) or by specific chromosomal genes (53) and can influence pathogenicity. Limited investigations of the relevance and widespread presence of such modifications have shown that most S. Typhimurium and S. Enteritidis strains are glucosylated and O acetylated, with more diversity reported for S. Enteritidis compared to S. Typhimurium (54) . O-acetylation and glucosylation can affect the three-dimensional structure of the OAg molecule and change conformational epitopes. Comparing conjugates made with OAg from three different strains (D23580, NVGH1792, and LT2), we could find differences in both immunogenicity and SBA activity. Considering that the MW distributions and OAg/CRM 197 ratios for the three conjugates were very similar, such differences could be attributed to strain-specific OAg modifications. In terms of immunogenicity, the strain with highest O-acetylation and glucosylation levels (D23580) generated more IgG antibodies (Fig. 3c) . D23580 has O-acetylation levels similar to those of NVGH1792 but 5-foldhigher glucosylation levels, which may be a critical factor for immunogenicity. Considering that D23580 antibodies could equally bind to D23580 and NVGH1792 OAg in an ELISA (Fig. 3d) but not to LT2 OAg, it is possible that a large proportion of them recognize OAg O-acetylated epitopes on rhamnose. Although consistent with FACS data, where very little signal was found with serum from mice immunized with D23580 and NVGH1792 conjugates incubated with LT2 bacteria (Fig. 6) , we cannot rule out that the low ELISA responses obtained for all conjugate groups against LT2 OAg may also be due to poor binding of this OAg on ELISA plates. In contrast to what was found with D23580 and NVGH1792 conjugates, antibodies elicited by LT2 OAg conjugate could bind all three strains as determined by FACS, suggesting that these antibodies bind epitopes common to all of the three strains (Fig. 6) .
In terms of SBA, all conjugates synthesized using OAg from the three S. Typhimurium strains could induce bactericidal antibodies, with strong SBA activity obtained with as little as 1 anti-OAg ELISA unit (Fig. 5b) . Compared as a function of serum dilution (Fig. 5a ), LT2-conjugate serum required a higher concentration of serum than did D23580-and NVGH1792-conjugate sera to achieve the same growth inhibition, a finding consistent with the lower immunogenicity of the LT2 conjugate (Fig. 3c) . Once normalized for anti-OAg IgG serum levels, although D23580 and LT2 conjugates varied most for both O-acetylation and glucosylation levels, the anti-OAg IgG antibodies they induced showed similar bactericidal properties, whereas NVGH1792 induced higher SBA activity per ELISA unit (Fig. 5b) . It is not clear which NVGH1792-specific OAg feature is responsible for this, and further investigations are required. However, these data show that in synthesizing glycoconjugates against S. Typhimurium, the selection of the strain as OAg source is important, and different strains may result in candidate vaccines with different immunogenicity and antibodies with potentially different cross-reactivity (Fig. 6) . Using the in vivo Salmonella challenge study in mice, we were able to demonstrate the efficacy of the D23580 OAg-CRM 197 conjugate at reducing bacterial load in the liver and spleen.
An effective glycoconjugate vaccine candidate against invasive African S. Typhimurium should be highly immunogenic and able to elicit bactericidal antibodies. Our study indicates that these immunological characteristics are specifically influenced by OAg glucosylation, OAg MW, and the OAg/CRM 197 ratio. The strongest anti-OAg antibody responses were elicited by the conjugate containing OAg with the highest glucosylation levels, mixed or MMW OAg populations, and with an OAg/CRM 197 ratio optimized according to the OAg MW (in the present study, a wt/wt ratio of ϳ1.5 was the ratio that yielded the best conjugation efficiency). In addition, to generate bactericidal anti-OAg antibodies cross-protective against endemic invasive African S. Typhimurium strains, particular consideration should be given to the interplay of both O-acetylation and glucosylation levels.
To specifically address this last point, further studies are ongoing with additional conjugates made of OAg characterized by different O-acetylation (amount and position) and glucosylation levels. Sera produced in response to immunization with these conjugates will be tested against a broader range of clinical S. Typhimurium isolates.
